Center-Authored Papers

Filters: Author is Byrd, John C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2015.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):326-62. Abstract
Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM et al..  2015.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr. Leukemia & lymphoma. 56(11):3031-3037. Abstract
D
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE, Fisher RI et al..  2016.  Diffuse Large B-Cell Lymphoma Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(2):196-231. Abstract
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al..  2017.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020. Abstract
G
Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM et al..  2016.  Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.. British journal of haematology. Abstract
I
Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, Appelbaum FR, Tallman MS, Belch AR, Morrison VA et al..  2013.  Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(4):440-7. Abstract
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
N
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP et al..  2010.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Caimi P, Fayad LE et al..  2017.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3):293-311. Abstract
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE et al..  2016.  NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(9):1067-79. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE et al..  2013.  Non-Hodgkin's lymphomas, version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):257-72;quiz273. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L et al..  2012.  Non-Hodgkin's Lymphomas, version 3.2012.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(12):1487-98. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ et al..  2011.  Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.
P
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP et al..  2013.  A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leukemia.. Blood. Abstract
R
Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H et al..  2016.  Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.. British journal of haematology. Abstract